* The listed price of $30.00 for cultures and plasmids is for academic and non-profit users. Commercial and industrial users are charged $300.00 for each strain or plasmid and twice the listed price for media components. BACs and fosmids are $50.00 for academic and non-profit users and $500 for commercial/industry. For the Jonikas CLiP mutants, the price is $100.00 each for academic and non-profit users and commercial and industrial users are charged $500.00.

CC-4285 bop5-2; IC138; mt+ [2BA]

Name: CC-4285 bop5-2; IC138; mt+ [2BA]
SKU: CC-4285
Availability: InStock

$30.00

From Mary Porter, U of MN, March 2009

The bop5-2 (6F5) strain was co-transformed with a genomic fragment of the IC138 gene (plasmid pHx) and pSI103 by Cathy Perrone in the Porter lab. Positive transformants were selected by growth on paromomycin. The 2BA transformant contains the full-length IC138 gene and reassembles the IC138 sub-complex into the axoneme (IC138, IC97, LC7b, and FAP120).

The bop (bypass of paralysis) mutants were isolated by Dutcher et al. in a pf10 background, by selection for restoration of motility.

Dutcher SK, Gibbons W, Inwood WB. A genetic analysis of suppressors of the PF10 mutation in Chlamydomonas reinhardtii. Genetics. 1988 Dec;120(4):965-76. doi: 10.1093/genetics/120.4.965. PMID: 3224813; PMCID: PMC1203588.

Dutcher SK, Power J, Galloway RE, Porter ME. Reappraisal of the genetic map of Chlamydomonas reinhardtii. J Hered. 1991 Jul-Aug;82(4):295-301. doi: 10.1093/oxfordjournals.jhered.a111089. PMID: 1880392.

Bower R, VanderWaal K, O'Toole E, Fox L, Perrone C, Mueller J, Wirschell M, Kamiya R, Sale WS, Porter ME. IC138 defines a subdomain at the base of the I1 dynein that regulates microtubule sliding and flagellar motility. Mol Biol Cell. 2009 Jul;20(13):3055-63. doi: 10.1091/mbc.e09-04-0277. Epub 2009 May 6. PMID: 19420135; PMCID: PMC2704157.

CC-4285 bop5-2; IC138; mt+ [2BA]

Products

Support

Banner Photo Credit: Chlamydomonas reinhardtii zygotes were stained for immunofluorescence with anti-acetylated tubulin (green), anti-phospholipase D (red), and DAPI (blue) by Karl F. Lechtreck (University of Georgia) and George B. Witman (University of Massachusetts Medical School).

Any opinions, findings, and conclusions or recommendations expressed on this website are those of the author(s) and do not necessarily reflect the views of the National Science Foundation.

Cart